Want to join the conversation?
$LH 2Q15 Call: Covance drug development reported revenue growth on a constant currency basis of 1.8% over last year's pro forma revenue, had strong growth & margin expansion as toxicology market continues to improve. Central lab revenues increased on a sequential basis due to higher kit receipts and contributed strong new orders in the quarter.
Still in yesterday’s $PZZA shock. I thought everyone had more pizza this football season!!
$TSLA stock downgraded to sell from hold by brokerage firm CFRA Research. However, the firm lifted the price target by $35 to $240.
$LB shares have plummeted after a disappointing quarter.